Emergency BU Alert Boston University's Charles River Campus is cancelling evening classes on Monday, February 8, 2016. All academic and administrative activities (e.g. classes, seminars and meetings) that are scheduled to take place before 5:00 PM will meet as scheduled. Academic and administrative operations that are normally scheduled to occur after 5:00 PM will be cancelled. For detailed information on the Boston University Medical Campus, please go to: http://www.bu.edu/ehs/comm Please note: Employees in essential services must report as scheduled. Essential services include, but are not limited to, University Police, Facilities Management and Planning, University Dining Services, University Mail Services, Student Health Services, Environmental Health & Safety and Network Services. For the latest information please go to: http://www.bu.edu/today

Michael Y. Sherman


Boston University School of Medicine
Silvio Conte Building
72 E. Concord Street
Boston, MA 02118

Phone: (617) 638-5971
Lab Phone:
(617) 638-5339


PhD, Moscow University, Russia

BU Profile


Vladimir Gabai
Research Asst. Professor
Julia Yaglom
Research Asst. Professor
Anatoli Meriin

Research Interests

I. Research in my lab has focused on understanding the molecular mechanisms underlying the central role of the heat shock protein Hsp72 in cancer. In cancer cells Hsp72 is often expressed at very high levels, and its expression correlates with the aggressiveness of tumors. Recently we have found that Hsp72 regulates early stages of tumorigenesis. Indeed, Hsp72 can control signaling pathways initiated by major oncogenes, resulting in avoiding growth inhibition and facilitating cell proliferation and transformation.

Our research addresses several questions:

(1) How Hsp72 keeps the p53 pathway activated by PIK3CA oncogene under control?

(2) How Hsp72 prevents cell senescence activated by Her2 oncogene.

II. In a distinct project we study a process of aggregation of abnormal polypeptides. When chaperone and protein degradation machineries fail to handle abnormal proteins, they aggregate and cause cell toxicity, which may give rise to various neurological disorders. As the last line of defense, a special machinery has evolved that transports these toxic aggregates to a centrosome location via microtubules, which leads to relieve of toxicity. The resulting non-toxic single large aggregate is called aggresome.  Previously we have established a yeast model to study aggregation and toxicity of the disease-causing polypeptides with expanded polyglutamine domain. Now, using both yeast and mammalian systems, we are dissecting the pathway of aggresome formation.

Our current research within this project uses genetics and biochemical approaches to addresses the following questions:

(1) What cellular components are involved in aggresome formation?

(2) What signaling pathways control aggresome formation?

Research Themes

NeuroscienceCell Biology

Representative Publications